ZJU-ENS Joint Laboratory of Medicinal Chemistry, School of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Bioorg Med Chem. 2013 Oct 1;21(19):5936-44. doi: 10.1016/j.bmc.2013.07.051. Epub 2013 Aug 8.
A series of novel 3-substituted-indole derivatives with a benzyl tertiary amino moiety were designed, synthesized and evaluated as H3 receptor antagonists and free radical scavengers for Alzheimer's disease therapy. Most of these synthesized compounds exhibited moderate to potent antagonistic activities in CREs driven luciferase assay. In particular, compound 2d demonstrated the most favorable H3 receptor antagonistic activity with the IC50 value of 0.049μM. Besides, it also displayed high binding affinity to H3 receptor (Ki=4.26±2.55nM) and high selectivity over other three histamine receptors. Moreover, 2d and other two 3-substituted indole derivatives 1d and 3d exerted potent ABTS radical cation scavenging capacities similar to melatonin. Above results illustrate that 2d is an interesting lead for extensive optimization to explore new drug candidate for AD therapy.
设计、合成并评价了一系列具有苄基叔胺部分的新型 3-取代吲哚衍生物,作为 H3 受体拮抗剂和用于治疗阿尔茨海默病的自由基清除剂。这些合成的化合物大多数在 CREs 驱动的荧光素酶测定中表现出中等至较强的拮抗活性。特别是,化合物 2d 表现出最有利的 H3 受体拮抗活性,IC50 值为 0.049μM。此外,它还表现出对 H3 受体的高结合亲和力(Ki=4.26±2.55nM)和对其他三种组胺受体的高选择性。此外,2d 和另外两种 3-取代吲哚衍生物 1d 和 3d 表现出与褪黑素相似的强大 ABTS 自由基阳离子清除能力。以上结果表明,2d 是一个有趣的先导化合物,值得进一步优化,以探索用于 AD 治疗的新候选药物。